Intellia Therapeutics NTLA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Intellia Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's return on equity?
- Intellia Therapeutics (NTLA) reported return on equity of -56.3% in Q1 2026.
- How has Intellia Therapeutics's return on equity changed year-over-year?
- Intellia Therapeutics's return on equity increased by 2.7% year-over-year, from -57.9% to -56.3%.
- What is the long-term trend for Intellia Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Intellia Therapeutics's return on equity has grown at a 9.7% compound annual growth rate (CAGR), from -33.7% to -53.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.